Announcements Trials
Browse Landscape

Status

Unknown 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 81Observational 6Expanded_access 1

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 6Neoplasm Metastasis 2Stomach Neoplasms 1Neoplasm, Residual 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 60palbociclib 37Trastuzumab 31Letrozole 26Immunohistochemistry 26Drug Therapy 24Anastrozole 24Radiotherapy 21Gene Expression Profiling 20Amplified Fragment Length Polymorphism Analysis 20Mastectomy, Segmental 19Biopsy 19Tamoxifen 18exemestane 17Interviews as Topic 17ribociclib 16Mastectomy 16Fulvestrant 16Paclitaxel 15Magnetic Resonance Spectroscopy 15Psychiatric Rehabilitation 14High-Energy Shock Waves 14Polymerase Chain Reaction 13Observation 13Microarray Analysis 13Capecitabine 13trastuzumab deruxtecan 12Neoadjuvant Therapy 12Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Observational × Breast Neoplasms × Ado-Trastuzumab Emtansine × Clear all
NCT06663787 2026-05-13

HER2 CR

Nagoya City University

Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT04158258 2026-04-23

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Hoffmann-La Roche

Active not recruiting
2,907 enrolled
Breast

Breast Neoplasms

NCT05945927 2025-10-10

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Hoffmann-La Roche

Completed
178 enrolled
Breast

Breast Neoplasms

NCT05754502 2023-03-03

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Consorzio Oncotech

Unknown
300 enrolled
Breast

Breast Neoplasms

NCT04769050 2022-04-20

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Fudan University

Unknown
50 enrolled
Breast

Breast Neoplasms

NCT00833963 2019-05-16

MotHER

Genentech, Inc.

Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡